Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-04-18

Clinical Trial Update: Neoadjuvant QL1706 Therapy for ESCC [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating QL1706 for locally advanced resectable esophageal squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QL1706

Snippet

Sponsor: Shandong Provincial Hospital | Conditions: Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING